Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 1.35%71.53B | 1.44%49.34B | 5.76%24.84B | 8.35%92.75B | --70.58B | 13.27%48.64B | 20.87%23.49B | 15.50%85.6B | ---- | 12.10%42.94B |
| Operating income | 1.44%49.34B | 8.35%92.75B | 13.27%48.64B | 15.50%85.6B | 12.10%42.94B | |||||
| Operating expenses | -0.55%-38.74B | -8.93%-73.48B | -14.34%-38.53B | -14.75%-67.45B | -8.94%-33.7B | |||||
| Gross profit | 4.81%10.6B | 6.18%19.27B | 9.35%10.11B | 18.37%18.15B | 25.38%9.25B | |||||
| Selling expenses | ---- | -3.17%-4.87B | ---- | -5.21%-9B | ---- | -5.05%-4.72B | ---- | -6.01%-8.56B | ---- | -10.64%-4.49B |
| Administrative expenses | ---- | -2.82%-1.23B | ---- | -8.86%-2.5B | ---- | -17.02%-1.2B | ---- | -26.07%-2.3B | ---- | -19.61%-1.02B |
| Research and development expenses | ---- | -1.88%-1.67B | ---- | -24.01%-3.45B | ---- | -32.15%-1.64B | ---- | -21.41%-2.78B | ---- | -16.52%-1.24B |
| Profit from asset sales | ---- | 2,442.18%21.79M | 4,299.02%20.79M | -31.93%3.97M | -72.77%1.67M | -83.98%857.01K | --472.66K | 321.53%5.84M | --6.12M | 1,380.99%5.35M |
| Revaluation surplus | ---- | -55.52%75.74M | -60.24%30.81M | 1,596.07%253.16M | 282.26%220.19M | 186.99%170.27M | 1,153.32%77.5M | -33.73%14.93M | -902.32%-120.81M | -790.68%-195.73M |
| -Changes in the fair value of other assets | ---- | -55.52%75.74M | -60.24%30.81M | 1,596.07%253.16M | 282.26%220.19M | 186.99%170.27M | 1,153.32%77.5M | -33.73%14.93M | -902.32%-120.81M | -790.68%-195.73M |
| Impairment and provision | ---- | -490.52%-57.91M | 103.85%441.97K | 41.89%-135.96M | 98.10%-2.4M | 113.28%14.83M | ---11.48M | 45.08%-233.99M | -8,620.94%-126.83M | -87.74%-111.68M |
| -Other impairment is provision | ---- | -490.52%-57.91M | 103.85%441.97K | 41.89%-135.96M | 98.10%-2.4M | 113.28%14.83M | ---11.48M | 45.08%-233.99M | -8,620.94%-126.83M | -87.74%-111.68M |
| Special items of operating profit | ---- | 6.39%784.62M | ---- | 23.18%1.62B | ---- | 21.11%737.52M | ---- | 44.01%1.32B | ---- | 31.22%608.97M |
| Operating profit | 5.13%3.42B | 11.87%5.64B | 30.56%3.25B | 58.35%5.04B | 57.70%2.49B | |||||
| Financing cost | ---- | -139.65%-41.64M | -108.47%-6.07M | -81.96%36.9M | -95.49%13.95M | -63.13%105.02M | 321.33%71.63M | 12.31%204.59M | 223.92%308.98M | 326.42%284.87M |
| Adjustment items of earning before tax | ---- | -66.98%46.42M | ---- | -34.20%287.25M | ---- | -22.57%140.6M | ---- | -4.42%436.54M | ---- | 107.91%181.59M |
| Earning before tax | -2.11%3.43B | 4.96%5.97B | 18.27%3.5B | 48.66%5.68B | 70.58%2.96B | |||||
| Tax | ---- | 6.93%-436.68M | ---- | 5.92%-840.24M | ---- | 0.63%-469.2M | ---- | -18.38%-893.07M | ---- | -27.15%-472.19M |
| After-tax profit from continuing operations | -1.37%2.99B | 6.98%5.13B | 21.87%3.03B | 56.10%4.79B | 82.42%2.49B | |||||
| Earning after tax | -1.37%2.99B | 6.98%5.13B | 21.87%3.03B | 56.10%4.79B | 82.42%2.49B | |||||
| Minority profit | ---- | -10.08%912.08M | ---- | -9.00%1.78B | ---- | 2.57%1.01B | ---- | 19.56%1.95B | ---- | 33.12%988.91M |
| Profit attributable to shareholders | 0.67%2.81B | 3.01%2.08B | 14.89%1.13B | 17.99%3.35B | 2.79B | 34.61%2.02B | 59.48%981.25M | 97.73%2.84B | 141.45%1.5B | |
| Basic earnings per share | 0.49%2.06 | 2.70%1.52 | 15.28%0.83 | 18.27%2.46 | 2.05 | 35.78%1.48 | 60.00%0.72 | 98.10%2.08 | 136.96%1.09 | |
| Diluted earnings per share | 0.49%2.06 | 2.70%1.52 | 13.89%0.82 | 18.27%2.46 | 2.05 | 35.78%1.48 | 60.00%0.72 | 98.10%2.08 | 136.96%1.09 | |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Xinyong Zhonghe Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.